



(51) International Patent Classification:

A61P 31/04 (2006.01) C07C 239/18 (2006.01)

C07C 239/08 (2006.01)

(21) International Application Number:

PCT/US2019/037761

(22) International Filing Date:

18 June 2019 (18.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/686,416 18 June 2018 (18.06.2018) US

(71) Applicants: **THE GEORGE WASHINGTON UNIVERSITY A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION** [US/US]; 2121 I Street, N.W., Rice Hall Suite 601, Washington, District of Columbia 20052 (US). **WASHINGTON UNIVERSITY** [US/US]; One Brookings Drive, St. Louis, Missouri 63130 (US).

(72) Inventors: **DOWD, Cynthia**; 3338 Military Road, North West, Washington, District of Columbia 20015 (US).

ODOM JOHN, Audrey; 660 S. Euclid Avenue, St. Louis, Missouri 63110 (US). **EDWARDS, Rachel**; 4938 Parkview Place, St. Louis, Missouri 63110 (US). **HEIDEL, Kenneth M.**; 27 Randolph Place NW, Washington, District of Columbia 20001 (US). **WANG, Xu**; 1106 South Plum Point Drive, Exton, Pennsylvania 19341 (US). **CHOFOR, Rene**; 800 22nd Street, NW, Room 4490, Washington, District of Columbia 20052 (US).

(74) Agent: **LONGSWORTH, Gaby L.** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue N.W., Washington, District of Columbia 20005-3934 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: ANTIBIOTICS FOR VETERINARY STAPHYLOCOCCAL INFECTIONS




Fig. 1

(57) Abstract: The present disclosure provides method of treating or preventing a microbial infection caused by a prokaryotic pathogen in a subject, the method comprising administering a compound of Formula (I) as set forth in the specification. In one embodiment, the prokaryotic pathogen belongs to the genus *Staphylococcus*.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

ANTIBIOTICS FOR VETERINARY STAPHYLOCOCCAL INFECTIONS

GOVERNMENT LICENSE RIGHTS

[0001] This invention was made with government support under Grant No. R21 AI123808 and R01 AI123433 awarded by the National Institutes of Health. The U.S. government has certain rights in the invention.

BACKGROUND

1. Technical Field


[0002] The field of the present disclosure relates to compounds, methods, and pharmaceutical compositions for treating or preventing infection caused by *Staphylococcal* species.

2. Discussion of Related Art

[0003] Antimicrobial resistance is the ability of a microbe to resist the effects of an antibiotic. This means that microbes are not killed by the antibiotic and can continue to grow. There is a growing burden of antimicrobial resistance in animals. The key bacterial pathogens in infections, e.g., skin and soft tissue infections, in animals, are members of the *Staphylococcus intermedius* group. In particular, animals are increasingly infected by methicillin-resistant *Staphylococcus pseudintermedius* (MRSP) and methicillin-resistant *Staphylococcus schleiferi* (MRSS). New therapies are urgently needed.

[0004] Fosmidomycin (Scheme 1, **1a**), isolated from *Streptomyces lavendulae*, is a potent inhibitor of *P. falciparum* DXR ($IC_{50} = 0.034 \mu M$). FR900098 (Scheme 1, **1b**), the *N*-acetyl analog of fosmidomycin isolated from *Streptomyces rubellomurinus*, is roughly equipotent to fosmidomycin (*P. falciparum* DXR $IC_{50} = 0.024 \mu M$). While these two natural products have submicromolar inhibition of *P. falciparum* growth ($IC_{50} = 0.09$ - $0.35 \mu M$), their use as a single drug therapy is limited by low bioavailability, short serum half-life, and malaria recrudescence.

- 2 -




Scheme 1

[0005] WO 2019/005982 and US 2019/0030056 disclose α,β -unsaturated analogs of fosmidomycin that inhibit microbial infections caused by eukaryotic pathogens.

BRIEF SUMMARY OF THE INVENTION

[0006] Applicant has discovered that compounds of the present disclosure are not active against *S. aureus* pathogens but are active against other *Staphylococcus* pathogens such as *S. schleferi*, *S. pseudintermedius*, and/or *S. chromogenes*. This selectivity among prokaryotic *Staphylococcus* pathogens was unexpected.

[0007] In one aspect, the present disclosure provides a compound of Formula (I):



wherein:

[0008] X is selected from the group consisting of Na, H, and $\text{CH}(\text{R}_1)\text{OC}(=\text{O})\text{R}_2$;

[0009] Y is selected from the group consisting of Na, H, and $\text{CH}(\text{R}_1)\text{OC}(=\text{O})\text{R}_2$;

[0010] Z is selected from the group consisting of hydrogen, $\text{C}_1\text{-C}_6$ alkyl, optionally substituted aryl, and aralkyl;

[0011] each R_1 is independently selected from the group consisting of a hydrogen, $\text{C}_1\text{-C}_6$ alkyl, and optionally substituted aryl;

[0012] each R_2 is independently selected from the group consisting of an optionally substituted $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_2\text{-C}_6$ alkenyl, optionally substituted $\text{C}_3\text{-C}_6$ cycloalkyl, and optionally substituted aryl, or a pharmaceutically acceptable salt thereof.

[0013] In another aspect, the present disclosure provides a composition comprising:

[0014] (i) a compound of Formula (I), or a pharmaceutically acceptable salt thereof; and
(ii) a pharmaceutically acceptable excipient.

[0015] In another aspect, the present disclosure provides a method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

BRIEF DESCRIPTION OF DRAWINGS

[0016] Fig. 1 is a bar graph showing that fosmidomycin (FSM), FR900098, and representative compounds of Formula (I) are bacteriostatic in *S. schleferi*, *S. pseudintermedius*, and *S. chromogenes*.

[0017] Fig. 2 is a bar graph showing DXP metabolite analysis of *S. pseudintermedius* treated with FSM and RCB-185.

[0018] Fig. 3 is a bar graph showing MEP metabolite analysis of *S. pseudintermedius* treated with FSM and RCB-185.

[0019] Fig. 4 is a bar graph showing CDPME metabolite analysis of *S. pseudintermedius* treated with FSM and RCB-185.

[0020] Fig. 5 is a bar graph showing MEcPP metabolite analysis of *S. pseudintermedius* treated with FSM and RCB-185.

[0021] Fig. 6 is a bar graph showing HDMAPP metabolite analysis of *S. pseudintermedius* treated with FSM and RCB-185.

[0022] Fig. 7 is a bar graph showing IPP/DMAPP metabolite analysis of *S. pseudintermedius* treated with FSM and RCB-185.


[0023] Fig. 8 is bar graph showing the carotenoid analysis of FSM and RCB-185 at the concentrations indicated.

DETAILED DESCRIPTION OF THE INVENTION

[0024] Some embodiments of the current invention are discussed in detail below. In describing embodiments, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. A person skilled in the relevant art will recognize that other equivalent components can be employed and other methods developed without departing from the

broad concepts of the current invention. All references cited in this specification, including the Examples sections, are incorporated by reference as if each had been individually incorporated.

[0025] In one embodiment, the present disclosure provides a compound of Formula (I):



wherein:

[0026] X is selected from the group consisting of Na, hydrogen, and $\text{CH}(\text{R}_1)\text{OC}(=\text{O})\text{R}_2$;

[0027] Y is selected from the group consisting of Na, hydrogen, and $\text{CH}(\text{R}_1)\text{OC}(=\text{O})\text{R}_2$;

[0028] Z is selected from the group consisting of hydrogen, C_1 - C_6 alkyl, optionally substituted aryl, and aralkyl;

[0029] each R_1 is independently selected from the group consisting of a hydrogen, C_1 - C_6 alkyl, and optionally substituted aryl;

[0030] each R_2 is independently selected from the group consisting of an optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, optionally substituted C_3 - C_6 cycloalkyl, and optionally substituted aryl,

[0031] or a pharmaceutically acceptable salt thereof.








[0032] In another embodiment, the present disclosure provides a compound of Formula (I), wherein X is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$, or a pharmaceutically acceptable salt thereof.







[0033] In another embodiment, the present disclosure provides a compound of Formula (I), wherein Y is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$, or a pharmaceutically acceptable salt thereof.

[0034] In another embodiment, the present disclosure provides a compound of Formula (I), wherein Z is selected from the group consisting of hydrogen, methyl, phenyl, and $-(\text{CH}_2)_3\text{Ph}$, or a pharmaceutically acceptable salt thereof.

[0035] In another embodiment, the present disclosure provides a compound of Formula (I) selected from any one or more of the compounds of Table 1, or a pharmaceutically acceptable salt thereof.


Table 1

Formula	Structure	ID
II		RCB-185
III		ERJ-207
V		JXW-572
VI		JXW-573
VII		KMH-102
VIII		JXW-189
IX		JXW-168

X		CSD-101
XI		CSD-102
XII		CSD-103
XIII		CSD-104
XIV		CSD-105
XV		CSD-106

XVI		CSD-107
XVII		CSD-108

[0036] In another embodiment, the present disclosure provides a compound having Formula (XVIII):



or a pharmaceutically acceptable salt thereof.

[0037] In another embodiment, the present disclosure provides a composition comprising:

(i) a compound of Formula (I), or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable excipient.

[0038] In another embodiment, the present disclosure provides a composition comprising:

(i) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$; and (ii) a pharmaceutically acceptable excipient.

[0039] In another embodiment, the present disclosure provides a composition comprising:

(i) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$; and (ii) a pharmaceutically acceptable excipient.

[0040] In another embodiment, the present disclosure provides a composition comprising:

(i) a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is selected from the group consisting of hydrogen, methyl, phenyl, and $-(\text{CH}_2)_3\text{Ph}$; and (ii) a pharmaceutically acceptable excipient.

- [0041] In another embodiment, the present disclosure provides a composition comprising: (i) a compound of Formula (I) selected from any one or more of the compounds of Table 1, or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable excipient.
- [0042] In another embodiment, the present disclosure provides a method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- [0043] In another embodiment, the present disclosure provides a method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$.
- [0044] In another embodiment, the present disclosure provides a method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Y is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$.
- [0045] In another embodiment, the present disclosure provides a method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is selected from the group consisting of hydrogen, methyl, phenyl and $-(\text{CH}_2)_3\text{Ph}$.
- [0046] In another embodiment, the present disclosure provides a method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I) selected from any one or more of the compounds of Table 1, or a pharmaceutically acceptable salt thereof.
- [0047] In another embodiment, the present disclosure provides a method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of fosmidomycin or FR-900098, or a pharmaceutically acceptable salt thereof.

- [0048] In another embodiment, the present disclosure provides a method for treating or preventing a microbial infection in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (XVIII), or a pharmaceutically acceptable salt thereof.
- [0049] In another embodiment, the microbial infection is caused by a prokaryotic pathogen.
- [0050] In another embodiment, the compound of Formula (I) inhibits a function of an enzyme in a methylerythritol phosphate (MEP) pathway.
- [0051] In another embodiment, the prokaryotic pathogen belongs to the genus *Staphylococcus*.
- [0052] In another embodiment, the prokaryotic pathogen is *S. schleferi*, *S. pseudintermedius*, or *S. chromogenes*.
- [0053] In another embodiment, the microbial infection is a *Staphylococcal* infection.
- [0054] In another embodiment, the compound of Formula (I) inhibits the function of the enzyme by binding to the enzyme.
- [0055] In another embodiment, the enzyme is Dxr.
- [0056] In another embodiment, the compound of Formula (I) is administered in combination with an effective amount of an additional compound or composition, wherein the additional compound or composition treats or prevents the microbial infection or a secondary infection or a secondary symptom.
- [0057] In another embodiment, the present disclosure provides a method for inhibiting the growth of a prokaryotic pathogen, the method comprising contacting the prokaryotic pathogen with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
- [0058] In another embodiment, the present disclosure provides a method for inhibiting the growth of a prokaryotic pathogen, the method comprising contacting the prokaryotic pathogen with effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein X is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$.
- [0059] In another embodiment, the present disclosure provides a method for inhibiting the growth of a prokaryotic pathogen, the method comprising contacting the prokaryotic pathogen with an effective amount of a compound of Formula (I), or a pharmaceutically

acceptable salt thereof, wherein Y is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$.

[0060] In another embodiment, the present disclosure provides a method for inhibiting the growth of a prokaryotic pathogen, the method comprising contacting the prokaryotic pathogen with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is selected from the group consisting of hydrogen, methyl, phenyl and $-(\text{CH}_2)_3\text{Ph}$.


[0061] In another embodiment, the present disclosure provides a method for inhibiting the growth of a prokaryotic pathogen, the method comprising contacting the prokaryotic pathogen with an effective amount of a compound of Formula (I) selected from any one or more of the compounds of Table 1, or a pharmaceutically acceptable salt thereof.

[0062] In another embodiment, the present disclosure provides a method for inhibiting the growth of a prokaryotic pathogen, the method comprising contacting the prokaryotic pathogen with an effective amount of fosmidomycin or FR-900098, or a pharmaceutically acceptable salt thereof.

[0063] In another embodiment, the present disclosure provides a method for inhibiting the growth of a prokaryotic pathogen, the method comprising contacting the prokaryotic pathogen with an effective amount of a compound of Formula (XVIII), or a pharmaceutically acceptable salt thereof.

[0064] In another embodiment, the prokaryotic pathogen belongs to the genus *Staphylococcus*.


[0065] In another embodiment, the present disclosure relates to a method for treating or preventing a microbial infection in a subject in need thereof comprising administering to the subject an effective amount of a composition or formulation comprising a small molecule having the structure of Formula (I):




or pharmaceutically acceptable salts and prodrugs thereof, where X is selected from the group consisting of Na, H, $\text{CH}(\text{R}_1)\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, $\text{CH}_2\text{OC}(=\text{O})\text{R}_2$ and POM, where Y is selected from the group consisting of Na, H, and POM, where Z is CH_3 , H,

unsubstituted Phenyl or substituted Phenyl, where R_1 is selected from the group consisting of a methyl group, an ethyl group, a propyl group and an aryl group, where R_2 is selected from the group consisting of an unsubstituted aryl group, an unsubstituted alkyl group, an unsubstituted alkenyl group, a substituted aryl group, a substituted alkyl group, and a substituted alkenyl group, where POM is $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, where the microbial infection is caused by a prokaryotic pathogen, and where the small molecule inhibits a function of an enzyme in a methylerythritol phosphate (MEP) pathway.


- [0066] Some embodiments of the present disclosure relate to the method above, where the prokaryotic pathogen belongs to the genus *Staphylococcus*.
- [0067] Some embodiments of the present disclosure relate to the method above, where the small molecule inhibits the function of the enzyme by binding to the enzyme.
- [0068] Some embodiments of the present disclosure relate to the method above, where the enzyme is Dxr.
- [0069] Some embodiments of the present disclosure relate to the method above, where the effective amount is between 0.1 mg/kg of body weight of the subject to 300 mg/kg of body weight of the subject.
- [0070] Some embodiments of the present disclosure relate to the method above, where the composition or formulation is administered to the subject as a single dose or as multiple doses over the course of a single day or multiple days.
- [0071] Some embodiments of the present disclosure relate to the method above, where the composition or formulation is administered to the subject for at least 1 day.
- [0072] Some embodiments of the present disclosure relate to the method above, further comprising administering to the subject an additional composition or formulation, wherein the additional composition or formulation treats the microbial infection or a secondary infection or a secondary symptom.
- [0073] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (II):




[0074] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (III):




[0075] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (IV):




[0076] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (V):



[0077] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (VI):



[0078] In another embodiment, the present disclosure relates to a method for inhibiting growth of a prokaryotic pathogen comprising contacting the prokaryotic pathogen with effective amount of a small molecule having the structure of Formula (I):



[0079] or pharmaceutically acceptable salts and prodrugs thereof, where X is selected from the group consisting of Na, H, $\text{CH}(\text{R}_1)\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, $\text{CH}_2\text{OC}(=\text{O})\text{R}_2$ and POM, where Y is selected from the group consisting of Na, H, and POM, where Z is CH_3 , H, unsubstituted Phenyl or substituted Phenyl, where R^1 is selected from the group consisting of a methyl group, an ethyl group, a propyl group and an aryl group, where R_2 is selected from the group consisting of an unsubstituted aryl group, an unsubstituted alkyl group, an unsubstituted alkenyl group, a substituted aryl group, a substituted alkyl group, and a substituted alkenyl group, where POM is $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and where the small molecule inhibits a function of an enzyme in a methylerythritol phosphate (MEP) pathway.


[0080] Some embodiments of the present disclosure relate to the method above, where the prokaryotic pathogen belongs to the genus *Staphylococcus*.

[0081] Some embodiments of the present disclosure relate to the method above, where the small molecule inhibits the function of the enzyme by binding to the enzyme.


[0082] Some embodiments of the present disclosure relate to the method above, where the enzyme is Dxr.

[0083] Some embodiments of the present disclosure relate to the method above, further comprising contacting the prokaryotic pathogen with an additional composition or formulation, wherein the additional composition inhibits a biological process of the prokaryotic pathogen.

[0084] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (II):




[0085] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (III):




(III).

[0086] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (IV):




(IV).

[0087] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (V):




(V).

[0088] Some embodiments of the present disclosure relate to the method above, where the small molecule has the structure of Formula (VI):



(VI).

[0089] In another embodiment, the present disclosure relates a pharmaceutical composition comprising a small molecule having the structure of Formula (I):




(I),


[0090] or pharmaceutically acceptable salts and prodrugs thereof; and a pharmaceutically acceptable excipient, where X is selected from the group consisting of Na, H, CH(R₁)OC(=O)C(CH₃)₃, CH₂OC(=O)R₂ and POM, where Y is selected from the group

consisting of Na, H, and POM, where Z is CH₃, H, unsubstituted Phenyl or substituted Phenyl, where R₁ is selected from the group consisting of a methyl group, an ethyl group, a propyl group and an aryl group, where R₂ is selected from the group consisting of an unsubstituted aryl group, an unsubstituted alkyl group, an unsubstituted alkenyl group, a substituted aryl group, a substituted alkyl group, and a substituted alkenyl group, and where POM is CH₂OC(=O)C(CH₃)₃.


[0091] Some embodiments of the present disclosure relate to the pharmaceutical composition above, where the small molecule has the structure of Formula (II):




[0092] Some embodiments of the present disclosure relate to the pharmaceutical composition above, where the small molecule has the structure of Formula (III):




[0093] Some embodiments of the present disclosure relate to the pharmaceutical composition above, where the small molecule has the structure of Formula (IV):



[0094] Some embodiments of the present disclosure relate to the pharmaceutical composition above, where the small molecule has the structure of Formula (V):




[0095] Some embodiments of the current invention relate to the pharmaceutical composition above, where the small molecule has the structure of Formula (VI):



[0096] The disclosure also provides the following particular embodiments.

[0097] Embodiment I. A method for treating or preventing a microbial infection in a subject in need thereof comprising administering to the subject an effective amount of a composition or formulation comprising a small molecule having the structure of Formula (I):



or pharmaceutically acceptable salts and prodrugs thereof,

[0098] wherein X is selected from the group consisting of Na, H, $\text{CH}(\text{R}_1)\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, $\text{CH}_2\text{OC}(=\text{O})\text{R}_2$ and POM,

[0099] wherein Y is selected from the group consisting of Na, H, and POM,

[0100] wherein Z is CH_3 , H, unsubstituted Phenyl or substituted Phenyl,

[0101] wherein R_1 is selected from the group consisting of a methyl group, an ethyl group, a propyl group and an aryl group,

[0102] wherein R_2 is selected from the group consisting of an unsubstituted aryl group, an unsubstituted alkyl group, an unsubstituted alkenyl group, a substituted aryl group, a substituted alkyl group, and a substituted alkenyl group,


[0103] wherein POM is $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$,

[0104] wherein the microbial infection is caused by a prokaryotic pathogen, and


[0105] wherein the small molecule inhibits a function of an enzyme in a methylerythritol phosphate (MEP) pathway.

[0106] Embodiment 2. The method of Embodiment 1, wherein the prokaryotic pathogen belongs to the genus *Staphylococcus*.


- [0107] Embodiment 3. The method of Embodiment 1, wherein the small molecule inhibits the function of the enzyme by binding to the enzyme.
- [0108] Embodiment 4. The method of Embodiment 1, wherein the enzyme is Dxr.
- [0109] Embodiment 5. The method of Embodiment 1, wherein the effective amount is between 0.1 mg/kg of body weight of the subject to 300 mg/kg of body weight of the subject.
- [0110] Embodiment 6. The method of Embodiment 1, wherein the composition or formulation is administered to the subject as a single dose or as multiple doses over the course of a single day or multiple days.
- [0111] Embodiment 7. The method of Embodiment 1, wherein the composition or formulation is administered to the subject for at least 1 day.
- [0112] Embodiment 8. The method of Embodiment 1, further comprising administering to the subject an additional composition or formulation, wherein the additional composition or formulation treats the microbial infection or a secondary infection or a secondary symptom.
- [0113] Embodiment 9. The method of Embodiment 1, wherein the small molecule has the structure of Formula (II):




- [0114] Embodiment 10. The method of Embodiment 1, wherein the small molecule has the structure of Formula (III):




- [0115] Embodiment 11. The method of Embodiment 1, wherein the small molecule has the structure of Formula (IV):




[0116] Embodiment 12. The method of Embodiment 1, wherein the small molecule has the structure of Formula (V):



[0117] Embodiment 13. The method of Embodiment 1, wherein the small molecule has the structure of Formula (VI):



[0118] Embodiment 14. A method for inhibiting growth of a prokaryotic pathogen comprising contacting the prokaryotic pathogen with effective amount of a small molecule having the structure of Formula (I):



[0119] or pharmaceutically acceptable salts and prodrugs thereof,


[0120] wherein X is selected from the group consisting of Na, H, CH(R₁)OC(=O)C(CH₃)₃, CH₂OC(=O)R₂ and POM,

[0121] wherein Y is selected from the group consisting of Na, H, and POM,


[0122] wherein Z is CH₃, H, unsubstituted Phenyl or substituted Phenyl,

[0123] wherein R₁ is selected from the group consisting of a methyl group, an ethyl group, a propyl group and an aryl group,


- [0124] wherein R_2 is selected from the group consisting of an unsubstituted aryl group, an unsubstituted alkyl group, an unsubstituted alkenyl group, a substituted aryl group, a substituted alkyl group, and a substituted alkenyl group,
- [0125] wherein POM is $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$,
- [0126] wherein the small molecule inhibits a function of an enzyme in a methylerythritol phosphate (MEP) pathway.
- [0127] Embodiment 15. The method of Embodiment 14, wherein the prokaryotic pathogen belongs to the genus *Staphylococcus*.
- [0128] Embodiment 16. The method of Embodiment 14, wherein the small molecule inhibits the function of the enzyme by binding to the enzyme.
- [0129] Embodiment 17. The method Embodiment claim 14, wherein the enzyme is Dxr.
- [0130] Embodiment 18. The method of Embodiment 14, further comprising contacting the prokaryotic pathogen with an additional composition or formulation, wherein the additional composition inhibits a biological process of the prokaryotic pathogen.
- [0131] Embodiment 19. The method of Embodiment 14, wherein the small molecule has the structure of Formula (II):




- [0132] Embodiment 20. The method of claim Embodiment 14, wherein the small molecule has the structure of Formula (III):




- [0133] Embodiment 21. The method of Embodiment 14, wherein the small molecule has the structure of Formula (IV):




[0134] Embodiment 22. The method of Embodiment 14, wherein the small molecule has the structure of Formula (V):



[0135] Embodiment 23. The method of Embodiment 14, wherein the small molecule has the structure of Formula (VI):



[0136] Embodiment 24. A pharmaceutical composition comprising a small molecule having the structure of Formula (I):



[0137] or pharmaceutically acceptable salts and prodrugs thereof; and a pharmaceutically acceptable excipient,

[0138] wherein X is selected from the group consisting of Na, H, CH(R₁)OC(=O)C(CH₃)₃, CH₂OC(=O)R₂ and POM,

[0139] wherein Y is selected from the group consisting of Na, H, and POM,


[0140] wherein Z is CH₃, H, unsubstituted Phenyl or substituted Phenyl,

[0141] wherein R₁ is selected from the group consisting of a methyl group, an ethyl group, a propyl group and an aryl group,


[0142] wherein R_2 is selected from the group consisting of an unsubstituted aryl group, an unsubstituted alkyl group, an unsubstituted alkenyl group, a substituted aryl group, a substituted alkyl group, and a substituted alkenyl group, and

[0143] wherein POM is $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$.


[0144] Embodiment 25. The pharmaceutical composition of Embodiment 24, wherein the small molecule has the structure of Formula (II):




[0145] Embodiment 26. The pharmaceutical composition of Embodiment 24, wherein the small molecule has the structure of Formula (III):




[0146] Embodiment 27. The pharmaceutical composition of Embodiment 24, wherein the small molecule has the structure of Formula (IV):



[0147] Embodiment 28. The pharmaceutical composition of Embodiment 24, wherein the small molecule has the structure of Formula (V):



[0148] Embodiment 29. The pharmaceutical composition of Embodiment 24, wherein the small molecule has the structure of Formula (VI):



Definitions

- [0149] As used throughout the term "subject" refers to a mammal. In some embodiments, the mammal is human. In some embodiments, the mammal is an animal. In some embodiments, the animal is a companion animal/household pet. In some embodiments, the animal is livestock or other large farm animal. In some embodiments, the animal is a cow, sheep, pig, horse, dog or cat.
- [0150] The term "in need thereof" refers to a subject infected with a microbial pathogen or at risk of becoming infected by the microbial pathogen. In some embodiments, the pathogen is a prokaryotic pathogen. In some embodiments, the pathogen belongs to the genus *Staphylococcus*.
- [0151] As used throughout, the phrase an "effective amount" of a compound of this disclosure is measured by the therapeutic effectiveness of the compound, wherein at least one adverse effect of a disorder is ameliorated or alleviated. More specifically, administering a compound or composition results in complete or at least partial inhibition of a metabolic pathway or other biological processes in a pathogen. In addition, an effective amount is sufficient to result in at least some degree of alleviation or prevention of an infection caused by a pathogen, or prevention of an infection by the pathogen.
- [0152] The terms "treating or preventing" are intended to include preventing, eradicating, or inhibiting the resulting increase of undesired physiological activity associated with a disorder or infection, for example, in the context of the therapeutic or prophylactic methods of the invention. In another embodiment, the term treating or preventing includes antagonistic effects, e.g., diminishment of the activity or production of mediators of a disorder.
- [0153] As used herein and unless otherwise indicated, the term "formulation" refers to a composition comprising a compound of the present disclosure that is described in a particular dosage form (e.g., tablet) or with a particular dosage amount.

- [0154] When administered to a subject (e.g., to an animal for veterinary use or to a human for clinical use), the compounds of the invention can be optionally administered in isolated form.
- [0155] The phrase "pharmaceutically acceptable salt(s)," as used herein includes but is not limited to salts of acidic or basic groups that may be present in compounds of the present disclosure. Compounds in the present disclosure that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions including, but not limited to, sulfuric, citric, maleic, acetic, oxalic, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts. Compounds in the present disclosure that include an amino moiety may form pharmaceutically acceptable salts with various amino acids, in addition to the acids mentioned above. Compounds in the present disclosure that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include alkali metal or alkaline earth metal salts and ammonium salts, for example, calcium, magnesium, sodium, potassium, lithium, zinc, potassium, and iron salts.
- [0156] The phrase "pharmaceutically acceptable excipient" may be any substance, not itself a therapeutic agent, used as a carrier, diluent, adjuvant, binder, and/or vehicle for delivery of a therapeutic agent to a patient, or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a compound or pharmaceutical composition into a unit dosage form for administration. Pharmaceutically acceptable excipients are known in the pharmaceutical arts and are disclosed, for example, in Remington: The Science and Practice of Pharmacy, 21st Ed. (Lippincott Williams & Wilkins, Baltimore, MD, 2005). As will be known to those in the art, pharmaceutically acceptable excipients can provide a variety of functions and can be described as wetting agents, buffering agents, suspending agents, lubricating agents,

emulsifiers, disintegrants, absorbents, preservatives, surfactants, colorants, flavorants, and sweeteners.

[0157] The therapeutic methods provided herein comprise administering a compound of Formula (I) to a subject in an amount which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art. Typically, a compound of Formula (I) is administered in an amount from about 0.05 mg/kg to about 500 mg/kg, about 0.05 mg/kg to about 100 mg/kg, about 0.05 mg/kg to about 50 mg/kg, or about 0.05 mg/kg to about 10 mg/kg. In one embodiment, a compound of Formula (I) is administered in an amount from 0.1 mg/kg of body weight of the subject to 300 mg/kg of body weight of the subject. The dosage of a composition can be at any dosage including, but not limited to, about 0.05 mg/week to about 100 mg/week. Particular doses include 0.05, 1, 2, 5, 10, 20, 500, and 100 mg/kg once daily, or once weekly. In one embodiment, a compound of Formula (I) is administered one, two, three, four, or five times a week, i.e., a compound of Formula (I) is administered according to an intermittent dosing schedule. These dosages are exemplary, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this disclosure. In practice, the physician or veterinarian determines the actual dosing regimen that is most suitable for an individual subject, which can vary with the age, weight, and response of the particular subject.

[0158] The unit oral dose of a compound of Formula (I) may comprise from about 0.01 to about 1000 mg, e.g., about 0.01 to about 100 mg of a compound of Formula (I). In one embodiment, the unit oral dose of a compound of Formula (I) is 0.05 mg, 1 mg, 3 mg, 5 mg, 7 mg, 9 mg, 10 mg, 12 mg, 14 mg, 15 mg, 17 mg, 20 mg, 22 mg, 25 mg, 27 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg. The unit dose may be administered one or more times daily, e.g., as one or more tablets or capsules. The unit dose may also be administered by IV or subcutaneously to the subject. In practice, the physician or veterinarian determines the actual dosing regimen that is most suitable for an individual subject, which can vary with the age, weight, and response of the particular subject.

[0159] In addition to administering a compound of Formula (I) as a raw chemical, it may be administered as part of a pharmaceutical preparation, composition, or formulation. In some embodiments, the pharmaceutical preparation or composition can include one or

more pharmaceutically acceptable carriers, excipients, and/or auxiliaries. In some embodiments, the one or more carriers, excipients, and auxiliaries facilitate processing of a compound of Formula (I) into a preparation or composition which can be used pharmaceutically. The preparations, particularly those preparations which can be administered orally, subcutaneously, or topically, and which can be used for one type of administration, such as tablets, dragees, slow release lozenges and capsules, mouth rinses and mouth washes, gels, liquid suspensions, hair rinses, hair gels, and shampoos, and also preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by intravenous infusion, subcutaneous injection, topically or orally, contain from about 0.01 to 99 percent, in one embodiment from about 0.25 to 75 percent of active compound(s), together with the one or more carriers, excipients, and/or auxiliaries.

[0160] The compounds and pharmaceutical compositions provided herein may be administered to any subject which may experience the beneficial effects of a compound of Formula (I). Foremost among such subjects are veterinary animals (cows, sheep, pigs, horses, dogs, cats and the like) although the methods and compositions provided herein are not intended to be so limited. Other subjects include humans. In one embodiment, the subject is a veterinary animal having a microbial infection caused by one or more eukaryotic pathogens. In another embodiment, the subject is a veterinary animal having a *Staphylococcal* infection.

[0161] The pharmaceutical preparations provided herein are manufactured by means of conventional mixing, granulating, dragee-making, dissolving, or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.

[0162] Suitable excipients are, in particular, fillers such as saccharides, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as binders such as starch paste, using, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone. If desired, disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch,

cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate. Auxiliaries can be suitable flow-regulating agents and lubricants. Suitable auxiliaries include, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol. Dragee cores are provided with suitable coatings which, if desired, are resistant to gastric juices. For this purpose, concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used. Dye stuffs or pigments may be added to the tablets or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.

[0163] Other pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds are in one embodiment dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin. In addition, stabilizers may be added.

[0164] Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more of the active compounds with a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons. In addition, it is also possible to use gelatin rectal capsules which consist of a combination of the active compounds with a base. Possible base materials include, for example, liquid triglycerides, polyethylene glycols, or paraffin hydrocarbons.

[0165] In the present disclosure, the term "halo" or "halogen" as used by itself or as part of another group refers to -Cl, -F, -Br, or -I. In one embodiment, the halo is -Cl or -F. In one embodiment, the halo is -Cl.

[0166] In the present disclosure, the term "nitro" as used by itself or as part of another group refers to -NO₂.

[0167] In the present disclosure, the term "cyano" as used by itself or as part of another group refers to -CN.

[0168] In the present disclosure, the term "hydroxy" as used by itself or as part of another group refers to -OH.

[0169] In the present disclosure, the term "alkyl" as used by itself or as part of another group refers to unsubstituted straight- or branched-chain aliphatic hydrocarbons containing from one to twelve carbon atoms, i.e., C₁₋₁₂ alkyl, or the number of carbon atoms designated, e.g., a C₁ alkyl such as methyl, a C₂ alkyl such as ethyl, a C₃ alkyl such as propyl or isopropyl, a C₁₋₃ alkyl such as methyl, ethyl, propyl, or isopropyl, and so on. In one embodiment, the alkyl is a C₁₋₁₀ alkyl. In another embodiment, the alkyl is a C₁₋₆ alkyl. In another embodiment, the alkyl is a C₁₋₄ alkyl. In another embodiment, the alkyl is a straight chain C₁₋₁₀ alkyl. In another embodiment, the alkyl is a branched chain C₃₋₁₀ alkyl. In another embodiment, the alkyl is a straight chain C₁₋₆ alkyl. In another embodiment, the alkyl is a branched chain C₃₋₆ alkyl. In another embodiment, the alkyl is a straight chain C₁₋₄ alkyl. In another embodiment, the alkyl is a branched chain C₃₋₄ alkyl. In another embodiment, the alkyl is a straight or branched chain C₃₋₄ alkyl. Non-limiting exemplary C₁₋₁₀ alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, *iso*-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, and decyl. Non-limiting exemplary C₁₋₄ alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, and *iso*-butyl.

[0170] In the present disclosure, the term "cycloalkyl" as used by itself or as part of another group refers to saturated and partially unsaturated (containing one or two double bonds) cyclic aliphatic hydrocarbons containing one to three rings having from three to twelve carbon atoms, i.e., C₃₋₁₂ cycloalkyl, or the number of carbons designated. In one embodiment, the cycloalkyl group has two rings. In one embodiment, the cycloalkyl group has one ring. In another embodiment, the cycloalkyl group is chosen from a C₃₋₈ cycloalkyl group. In another embodiment, the cycloalkyl group is chosen from a C₃₋₆ cycloalkyl group. Non-limiting exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, and cyclopentenyl, cyclohexenyl.

[0171] In the present disclosure, the term "optionally substituted cycloalkyl" as used herein by itself or as part of another group means that the cycloalkyl as defined above is either unsubstituted or substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, nitro, cyano, -SCH₃, -SCF₃, -NR₁₀R₁₁, -C(=O)NR₁₀R₁₁, -C(=O)R₁₃, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy,

C₁₋₆ haloalkyl, haloalkoxy, optionally substituted C₃₋₁₂ cycloalkyl, optionally substituted C₆-C₁₄ aryl, optionally substituted 5- to 14-membered heteroaryl, and optionally substituted 3- to 14-membered heterocyclic ring, wherein R₁₀ and R₁₁ are independently selected from the group consisting of hydrogen and C₁₋₆ alkyl; or R₁₀ and R₁₁ taken together with the nitrogen atom to which they are attached form a 3- to 12-membered heterocyclic ring; and R₁₃ is C₁₋₄ alkyl.

[0172] In the present disclosure, the term "alkenyl" as used by itself or as part of another group refers to an alkyl group as defined above containing one, two or three carbon-to-carbon double bonds. In one embodiment, the alkenyl group is chosen from a C₂₋₆ alkenyl group. In another embodiment, the alkenyl group is chosen from a C₂₋₄ alkenyl group. Non-limiting exemplary alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, *sec*-butenyl, pentenyl, and hexenyl.

[0173] In the present disclosure, the term "optionally substituted alkenyl" as used herein by itself or as part of another group means that the alkenyl as defined above is either unsubstituted or substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, nitro, cyano, -SCH₃, -SCF₃, -NR₁₀R₁₁, -C(=O)NR₁₀R₁₁, -C(=O)R₁₃, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, haloalkoxy, optionally substituted C₃₋₁₂ cycloalkyl, optionally substituted C₆-C₁₄ aryl, optionally substituted 5- to 14-membered heteroaryl, and optionally substituted 3- to 14-membered heterocyclic ring, wherein R₁₀ and R₁₁ are independently selected from the group consisting of hydrogen and C₁₋₆ alkyl; or R₁₀ and R₁₁ taken together with the nitrogen atom to which they are attached form a 3- to 12-membered heterocyclic ring; and R₁₃ is C₁₋₄ alkyl.

[0174] In the present disclosure, the term "alkynyl" as used by itself or as part of another group refers to an alkyl group as defined above containing one to three carbon-to-carbon triple bonds. In one embodiment, the alkynyl has one carbon-to-carbon triple bond. In one embodiment, the alkynyl group is chosen from a C₂₋₆ alkynyl group. In another embodiment, the alkynyl group is chosen from a C₂₋₄ alkynyl group. Non-limiting exemplary alkynyl groups include ethynyl, propynyl, butynyl, 2-butynyl, pentynyl, and hexynyl groups. In the present disclosure, the term "optionally substituted alkynyl" as used herein by itself or as part of another group means that the alkynyl as defined above is either unsubstituted or substituted with one to three substituents independently selected from the group consisting of halogen, hydroxy, nitro, cyano, -SCH₃, -SCF₃, -

$\text{NR}_{10}\text{R}_{11}$, $-\text{C}(=\text{O})\text{NR}_{10}\text{R}_{11}$, $-\text{C}(=\text{O})\text{R}_{13}$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, haloalkoxy, optionally substituted C_{3-12} cycloalkyl, optionally substituted $\text{C}_6\text{-C}_{14}$ aryl, optionally substituted 5- to 14-membered heteroaryl, and optionally substituted 3- to 14-membered heterocyclic ring, wherein R_{10} and R_{11} are independently selected from the group consisting of hydrogen and C_{1-6} alkyl; or R_{10} and R_{11} taken together with the nitrogen atom to which they are attached form a 3- to 12-membered heterocyclic ring; and R_{13} is C_{1-4} alkyl.

[0175] In the present disclosure, the term "haloalkyl" as used by itself or as part of another group refers to an alkyl group substituted by one or more fluorine, chlorine, bromine and/or iodine atoms. In one embodiment, the alkyl group is substituted by one, two, or three fluorine and/or chlorine atoms. In another embodiment, the haloalkyl group is a C_{1-6} haloalkyl group. In another embodiment, the haloalkyl group is a C_{1-4} haloalkyl group. Non-limiting exemplary haloalkyl groups include fluoromethyl, 2-fluoroethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, and trichloromethyl groups.

[0176] In the present disclosure, the term "alkoxy" as used by itself or as part of another group refers to an alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl or optionally substituted alkynyl attached to a terminal oxygen atom. In one embodiment, the alkoxy group is chosen from a C_{1-4} alkoxy group. In another embodiment, the alkoxy group is chosen from a C_{1-6} alkoxy group. In another embodiment, the alkoxy group is chosen from a C_{1-4} alkyl attached to a terminal oxygen atom, e.g., methoxy, ethoxy, and *tert*-butoxy.


[0177] In the present disclosure, the term "haloalkoxy" as used by itself or as part of another group refers to a C_{1-4} haloalkyl attached to a terminal oxygen atom. Non-limiting exemplary haloalkoxy groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy.

[0178] In the present disclosure, the term "aryl" as used by itself or as part of another group refers to a monocyclic, bicyclic, or tricyclic aromatic ring system having from six to fourteen carbon atoms, i.e., $\text{C}_6\text{-C}_{14}$ aryl. Non-limiting exemplary aryl groups include phenyl (abbreviated as "Ph"), 1-naphthyl, 2-naphthyl, phenanthryl, anthracyl, indenyl, azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. In one embodiment, the aryl

group is chosen from phenyl, 1-naphthyl, or 2-naphthyl. In one embodiment, the aryl is a bicyclic or tricyclic C₁₀-C₁₄ aromatic ring system.

[0179] In the present disclosure, the term "optionally substituted aryl" as used herein by itself or as part of another group means that the aryl as defined above is either unsubstituted or substituted with one to five substituents independently selected from the group consisting of halogen, hydroxy, nitro, cyano, -SCH₃, -SCF₃, -NR₁₀R₁₁, -C(=O)NR₁₀R₁₁, -C(=O)R₁₃, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, haloalkoxy, optionally substituted C₃₋₁₂ cycloalkyl, optionally substituted C₆-C₁₄ aryl, optionally substituted 5- to 14-membered heteroaryl, and optionally substituted 3- to 14-membered heterocyclic ring, wherein R₁₀ and R₁₁ are independently selected from the group consisting of hydrogen and C₁₋₆ alkyl; or R₁₀ and R₁₁ taken together with the nitrogen atom to which they are attached form a 3- to 12-membered heterocyclic ring; and R₁₃ is C₁₋₄ alkyl.

[0180] In one embodiment, the optionally substituted aryl is an optionally substituted phenyl. In one embodiment, the optionally substituted phenyl has four substituents. In another embodiment, the optionally substituted phenyl has three substituents. In another embodiment, the optionally substituted phenyl has two substituents. In another embodiment, the optionally substituted phenyl has one substituent. Non-limiting exemplary substituted aryl groups include 2-methylphenyl, 2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl, 4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl, 3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl, 3,5-di-fluorophenyl, 3,4-di-chlorophenyl, 3,5-di-methylphenyl, 3,5-dimethoxy, 4-methylphenyl, 2-fluoro-3-chlorophenyl, and 3-chloro-4-fluorophenyl. The term optionally substituted aryl is meant to include groups having fused optionally substituted cycloalkyl and fused optionally substituted heterocyclic rings. Non-limiting examples include:



[0181] The terms "aralkyl" as used herein by itself or as part of another group refers to an alkyl substituted with one or two optionally substituted aryl groups. In one embodiment, the alkyl is substituted with one optionally substituted aryl group. In one embodiment, the aryl is an optionally substituted phenyl. In one embodiment, the alkyl is a C₁-C₆

alkyl. In another embodiment, the alkyl is a C₁-C₄ alkyl. In another embodiment, the alkyl is a C₁ or C₂ alkyl. In another embodiment, the alkyl is a C₃ alkyl. Non-limiting exemplary (aryl)alkyl groups include benzyl, phenethyl, phenpropyl, and -CHPh₂.

[0182] The embodiments illustrated and discussed above and in the following Examples section are intended only to teach those skilled in the art how to make and use the invention. In describing embodiments of the invention, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. The above-described embodiments of the invention may be modified or varied, without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.

EXAMPLES

EXAMPLE 1

Compound Synthesis

[0183] Compounds of Formula (I) were prepared as described in WO 2019/005982.

EXAMPLE 2

Activity of Compounds Against *Staphylococcus sp*

[0184] The growth inhibition of compounds of Formula (I) were evaluated against the following *Staphylococcus sp.* bacteria strains: *S. schleiferi* (S.s), *S. pseudintermedius* (S.p.), *S. chromogenes* (S.c), and *S. aureus* (S.a).

Growth inhibition of *Staphylococcus* species assay description

[0185] Overnight cultures were diluted 1:200 in LB media and grown at 37°C until the mid-logarithmic phase (OD₆₀₀ = 0.5 – 0.8). Cultures were diluted in a 96-well plate to 1 x 10⁵ in 150 µL LB media and treated with inhibitors at concentrations ranging from 2 nM to 100 µM. Bacteria were grown at 37°C for 20 h with cyclic shaking at 700 rpm in a FLUOstar Omega microplate reader (BMG Labtech). Growth was assessed over 20 h by

measuring the OD₆₀₀ at 20 min increments. The half-maximal inhibitory concentration (IC₅₀) values were determined during logarithmic growth using GraphPad Prism software. All experiments were performed at least in triplicate and data reported represent the mean $\pm$ SEM. *See* Edwards et al., "Potent, specific MEPicides for treatment of zoonotic staphylococci," BioRxiv 2019.

Minimum bactericidal (MBC) assay

[0186] Overnight cultures were diluted 1:200 in LB media and grown at 37°C until reaching mid-logarithmic phase of growth. Compounds were added to cultures at their respective IC₅₀ and at 10 x IC₅₀, and the bacteria were incubated at 37°C for 24 h while shaking. Cultures were serially diluted in Dulbecco's Phosphate Buffered Saline (PBS; Gibco) and plated on LB agar. Colonies were enumerated after overnight growth at 37°C. Values reflect the mean and standard deviations of at least three independent experiments. *See* Edwards et al., "Potent, specific MEPicides for treatment of zoonotic staphylococci," BioRxiv 2019.

[0187] The results of the growth inhibition and MBC assays are shown in Table 2 and Fig. 1. The activity of fosmidomycin (FSM) and FR-900098 is provided for comparison.

Table 2

Formula	ID	Bacterial IC ₅₀ μ M (Mean $\pm$ SD)			
		S.s.	S.p.	S.c.	S.a.
	fosmidomycin	0.78 $\pm$ 0.13	0.31 $\pm$ 0.04	0.31 $\pm$ 0.01	>100
II	RCB-185	0.10 $\pm$ 0.01	0.26 $\pm$ 0.03	0.07 $\pm$ 0.02	>100
III	ERJ-207	55.50 $\pm$ 2.41	57.07 $\pm$ 51.86	53.8 $\pm$ 4.8	>100
IV	FR-900098	41.06 $\pm$ 6.65	34.14 $\pm$ 6.54	17.3 $\pm$ 3.43	>100
V	JXW-572	4.17 $\pm$ 0.47	4.31 $\pm$ 0.51	1.13 $\pm$ 0.34	>100
VI	JXW-573	0.03 $\pm$ 0.00	0.21 $\pm$ 0.04	0.04 $\pm$ 0.00	>90
VII	KMH-102	0.21 $\pm$ 0.05			
VIII	JXW-189	1.3			
IX	JXW-168	8.7			
XVIII	RC-072	2.5			

EXAMPLE 3






Activity of Compounds Against Recombinant DXR Enzymes

[0188] The activity of compounds of Formula (I) were evaluated against recombinant DXR enzymes. The results for representative compounds of Formula (I) are shown in Table 3 (n = 3). The activity of fosmidomycin (FSM) and FR-900098 is provided for comparison.

DXR enzyme activity assay description.

[0189] Oxidation of NADPH to NADP⁺ as a result of substrate turnover was monitored at 340 nm in a POLARstar Omega microplate reader (BMG Labtech). The standard reaction had a final concentration of 62.5 nM purified DXR protein, 0.5 mM NADPH, 100 mM NaCl, 25 mM Tris pH 7.5, 10% glycerol, 1 mM MgCl₂ and 0.09 mg/mL BSA in 50 μ L volume per assay. Reactions were initiated by the addition of DOXP after 15 min incubation of the reaction mixture without DOXP at 37°C. Absorption at 340 nm was measured continuously for up to 45 min. For K_m [DOXP] determination, DOXP concentrations between 0 and 2 mM were tested at 0.5 mM NADPH. The linear range of enzyme activity was determined by varying the DXR concentration at 1 mM DOXP and 1 mM NADPH. IC₅₀ assays were performed using the standard reaction conditions with the respective amount of DXR inhibitor added to obtain the given final concentrations. Data points from at least three independent replicates were analyzed by nonlinear regression using GraphPad Prism software. Slopes of changing absorbance values were converted to (μM DOXP)(mg enzyme)⁻¹ s⁻¹ using a NADPH standard curve (data not shown). For the determination of the inhibitory constant K_i [FSM] of DXR, enzyme activity over a range of DOXP substrate concentrations between 0 and 2 mM was measured for FSM between 0 mM to 4 mM. Data points from at least three independent replicates were analyzed as described above. *See* Edwards et al., "Potent, specific MEPicides for treatment of zoonotic staphylococci," BioRxiv 2019.

Table 3

Structure	Compound	<i>S. chromogenes</i> IC ₅₀ μ M (mean $\pm$ SD)	<i>S. schleiferi</i> IC ₅₀ μ M (mean $\pm$ SD)
	Fosmidomycin	0.34 $\pm$ 0.08	0.67 $\pm$ 0.06
	ERJ-207	1.69 $\pm$ 0.45	3.31 $\pm$ 1.02
	RCB-185	>100	>100
	FR-900098	0.36 $\pm$ 0.12	1.00 $\pm$ 0.18
	JXW-572	0.17 $\pm$ 0.02	0.41 $\pm$ 0.11
	JXW-573	15.24 $\pm$ 2.36	12.56 $\pm$ 1.98

EXAMPLE 4

Metabolite Analysis of *Staphylococcus pseudintermedius*

[0190] Targeted metabolic profiling of MEP pathway intermediates in *S. pseudintermedius* was conducted. The results are shown in Figs. 2-7. See Wang and Dowd, *ACS Infect Dis.* 4(3):278-290 (2018).

Sample preparation for mass spectrometry analysis

[0191] Overnight cultures of *Staphylococcus* spp. were diluted 1:200 in LB media and grown at 37°C until reaching mid-logarithmic phase. Cultures were then treated for 2 h with FSM at 10x their IC₅₀ while shaking at 37°C. For normalization, the OD₆₀₀ was determined after 2 h of treatment with the DXR inhibitors. Cells were pelleted by centrifugation for 5 min at 3000 x g at 4°C. The supernatants were removed and cells were washed twice with PBS (Gibco). The supernatants were removed and the pellets stored at -80°C until analysis. MEP intermediates were extracted from the samples using glass beads (212-300 u) and 600 µL chilled H₂O: chloroform: methanol (3:5:12 v/v) spiked with PIPES (piperazine-N,N'-bis(2-ethanesulfonic acid) as internal standard. The cells were disrupted with the TissueLyser II instrument (Qiagen) using a microcentrifuge tube adaptor set pre-chilled for 2 min at 20 Hz. The samples were then centrifuged at 16,000 x g at 4°C for 10 min, the supernatants collected, and pellet extraction repeated once more. The supernatants were pooled and 300 µL chloroform and 450 µL of chilled water were added to the supernatants. The tubes were vortexed and centrifuged. The upper layer was transferred to a 2 mL tube PVDF filter (ThermoFisher, F2520-5) and centrifuged for 5 min at 4,000 x g at 4°C. The samples were transferred to new tubes and dried using a speed-vac. The pellets were re-dissolved in 100 µL of 50% acetonitrile.

LC-MS/MS analysis

[0192] For LC separation, Luna-NH₂ column (3 µm, 150 x 2 mm, Phenomenex) was used flowing at 0.4 mL/min. The gradient of the mobile phases A (20 mM ammonium acetate, pH 9.8, 5% acetonitrile) and B (100% acetonitrile) was as follows: 60% B for 1 min, to 6% B in 3 min, hold at 6% B for 5 min, then back to 60% B for 0.5 min. The LC system was interfaced with a Sciex QTRAP 6500⁺ mass spectrometer equipped with a TurboIonSpray (TIS) electrospray ion source. Analyst software (version 1.6.3)

was used to control sample acquisition and data analysis. The QTRAP 6500⁺ mass spectrometer was tuned and calibrated according to the manufacturer's recommendations. The metabolites were detected using MRM transitions that were previously optimized using standards. The instrument was set-up to acquire in negative mode. For quantification, an external standard curve was prepared using a series of standard samples containing different concentrations of metabolites and a fixed concentration of the internal standard. The limit of detection for 1-deoxy-D-xylulose 5-phosphate (DOXP), 4-diphosphocytidyl-2-C-methylerythritol (CDP-ME), and 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate (MEcPP) was 0.0064 μ M for a 10 μ L injection volume. Data reflect the mean and SD of at least three independent experiments. T-tests were used to test for significance between untreated (UNT) and drug-treated bacteria (Prism). *See* Edwards et al., "Potent, specific MEPicides for treatment of zoonotic staphylococci," *BioRxiv* 2019.

EXAMPLE 5


Carotenoid extraction and analysis

[0193] Mid-logarithmic phase cultures were treated with inhibitors at the IC_{50} , $0.2*IC_{50}$, and $5*IC_{50}$, and then incubated at 37°C for 24 h while shaking. Subsequently, 5 mL of samples were diluted to 3.2×10^9 CFU/mL and cells were pelleted by centrifugation for 1 min at 10,000 x g. Pellets were washed with deionized water and resuspended in 1 mL methanol. Samples were incubated at 55°C for 3 min, centrifuged at 15,000 x g for 1 min, and the supernatants measured photometrically at 465 nm. The data represent the mean $\pm$ SD from at least three independent experiments. One-way ANOVA was used to test for significance between the treatment groups and an untreated control (VassarStats). The results are shown in Fig. 8.

[0194] Having now fully described the compounds, compositions, and herein, it will be understood by those of skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the methods, compounds, and compositions provided herein or any embodiment thereof. All patents, patent applications, and publications cited herein are fully incorporated by reference herein in their entirety.

We Claim:

1. A method for treating or preventing a microbial infection caused by a prokaryotic pathogen in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I):



wherein:

X is selected from the group consisting of Na, hydrogen, and $\text{CH}(\text{R}_1)\text{OC}(=\text{O})\text{R}_2$;

Y is selected from the group consisting of Na, hydrogen, and $\text{CH}(\text{R}_1)\text{OC}(=\text{O})\text{R}_2$;

Z is selected from the group consisting of hydrogen, $\text{C}_1\text{-C}_6$ alkyl, optionally substituted aryl, and aralkyl;

each R_1 is independently selected from the group consisting of a hydrogen, $\text{C}_1\text{-C}_6$ alkyl, and optionally substituted aryl;

each R_2 is independently selected from the group consisting of an optionally substituted $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_2\text{-C}_6$ alkenyl, optionally substituted $\text{C}_3\text{-C}_6$ cycloalkyl, and optionally substituted aryl,

or a pharmaceutically acceptable salt thereof.







2. The method of claim 1, wherein X is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$.







3. The method of claims 1 or 2, wherein Y is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$.

4. The method of any one of claims 1-3, wherein Y is selected from the group consisting of Na, hydrogen, $\text{CH}_2\text{OC}(=\text{O})\text{C}(\text{CH}_3)_3$, and $\text{CH}_2\text{OC}(=\text{O})\text{Ph}$.


5. The method of any one of claims 1-4, wherein Z is selected from the group consisting of hydrogen, methyl, phenyl, and $-(\text{CH}_2)_3\text{Ph}$.

6. The method of claim 1, wherein the compound of Formula (I) is selected from the group consisting of:






- 40 -




or a pharmaceutically acceptable salt thereof.

7. The method of claim 6, wherein the compound of Formula (I) is:




or a pharmaceutically acceptable salt thereof.

8. The method of claim 6, wherein the compound of Formula (I) is:




or a pharmaceutically acceptable salt thereof.

9. The method of claim 6, wherein the compound of Formula (I) is:




or a pharmaceutically acceptable salt thereof.

10. The method of claim 6, wherein the compound of Formula (I) is:




or a pharmaceutically acceptable salt thereof.

11. The method of claim 6, wherein the compound of Formula (I) is:




or a pharmaceutically acceptable salt thereof.

12. The method of claim 6, wherein the compound of Formula (I) is:



or a pharmaceutically acceptable salt thereof.

13. A method for treating or preventing a microbial infection caused by a prokaryotic pathogen in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (XVIII):



or a pharmaceutically acceptable salt thereof.

14. The method of any one of claims 1-13, wherein the compound inhibits a function of an enzyme in a methylerythritol phosphate (MEP) pathway.

15. The method of any one of claims 1-13, wherein microbial infection is a *Staphylococcal* infection.

16. The method of any one of claims 1-15, further comprising administering an effective amount of an additional compound or composition, wherein the additional compound or composition treats or prevents the microbial infection.

17. The method of any one of claims 1-16, wherein the subject is a companion animal.

18. The method of claim 17, wherein the companion animal is a dog or cat.

19. The method of any one of claims 1-18, wherein the subject is a farm animal.

20. The method of claim 19, wherein the farm animal is a cow.




Fig. 1









Fig. 2

**Fig. 3**

**Fig. 4**

**Fig. 5**

**Fig. 6**

**Fig. 7**




Fig. 8

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/37761

A. CLASSIFICATION OF SUBJECT MATTER

IPC - A61P 31/04; C07C 239/08, 239/18 (2019.01)

CPC - A61P 31/04; C07C 239/08, 239/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 4,182,758 A (KAMIYA, T et al) 8 January 1980; column 2, lines 25-30; column 17, lines 60-65; column 19, lines 15-20; column 49, lines 35-40; column 57, lines 30-40; column 71, lines 20-25; claim 5	1-2, 3/1-2, 6, 8-9 --- 7, 10-12
Y	PUBCHEM. [(E)-3-[Acetyl(hydroxy)amino]prop-1-enyl]-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate. 17 March 2014, pages 1-7 [online], [retrieved on 2019-07-25]. Retrieved from the Internet <URL: https://pubchem.ncbi.nlm.nih.gov/compound/73212867 >; pages 2, 6	7, 10, 12
Y	PUBCHEM. [3-[Acetyl(hydroxy)amino]propyl-(benzoyloxymethoxy)phosphoryl]oxymethyl benzoate. 16 January 2012, pages 1-7 [online], [retrieved on 2019-07-25]. Retrieved from the Internet <URL: https://pubchem.ncbi.nlm.nih.gov/compound/54764844 >; pages 2, 6	11
A	PUBCHEM. [(E)-3-[Acetyl(hydroxy)amino]prop-2-enoyl]phosphonic acid. 05 December 2007, pages 1-5 [online], [retrieved on 2019-07-25]. Retrieved from the Internet <URL: https://pubchem.ncbi.nlm.nih.gov/compound/22644543 >; page 2	13
A	SMIDKOVA, M. Amidate Prodrugs of 9-[2-(Phosphonomethoxy)Ethyl]Adenine as Inhibitors of Adenylate Cyclase Toxin from Bordetella pertussis. Antimicrobial Agents and Chemotherapy, Vol. 58, No. 2, February 2014, pages 664-671; entire publication	1
A	JOSE, GS, et al. Structure-Activity Relationships of the MEPicides: N-acyl and O-linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis. ACS Infectious Diseases, Vol. 2, No. 12, 09 December 2016, pages 923-935; entire publication	1

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

26 July 2019 (26.07.2019)

Date of mailing of the international search report

09 AUG 2019

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US19/37761

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4-5, 14-20
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.